Sex-Specific Differences in Helicobacter pylori Eradication Outcomes: Treatment Success and Adverse Events in a Single Tertiary Center in South Korea
Abstract
Objectives Successful eradication of Helicobacter pylori is essential for improving patient outcomes and preventing gastric cancer; however, evidence regarding sex-specific differences in treatment success and adverse event profiles remain limited. This study investigated sex-based differences in eradication efficacy and treatment tolerability. Methods We retrospectively reviewed patients who underwent diagnostic testing, received eradication therapy, and completed post-treatment confirmation testing between 2003 and 2024 at Seoul National University Bundang Hospital. First-line therapy consisted of 10-day sequential therapy, while second-line treatment included 14-day bismuth-based quadruple therapy or 14-day moxifloxacin-based triple therapy. Treatment success and adverse events were evaluated by sex and treatment regimen. Results Females had lower eradication rates in the overall cohort. The intention-to-treat analysis showed significantly higher success rates in males compared to females in the total population (71.1% vs. 65.1%, p<0.001) and in sequential therapy (70.5% vs. 62.1%, p<0.001), although this pattern was not replicated in the per-protocol results. Adverse events were reported nearly twice as often in females, regardless of the regimen, which may partly explain the reduced rates of successful eradication and increased discontinuation. Conclusions Sex-based differences influence H. pylori eradication outcomes, with females showing lower treatment success rates…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.